Arcxis Gets Investment from In-Q-Tel | GenomeWeb

NEW YORK (GenomeWeb News) – Arcxis Biotechnologies said today that it has inked a partnership with In-Q-Tel to accelerate development and commercialization of the firm's nucleic acid sample preparation platform and diagnostic consumable product line.

Arcxis said the investment from In-Q-Tel is linked to the firm's recent round of private financing led by Claremont Creek Ventures, Kaiser Permanente Ventures, and Alafi Capital. The firm has not disclosed how much money it raised in that series B round, and it is not disclosing the amount of funding it has received from In-Q-Tel.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: certain genes repressed during memory formation, analysis of genomes from single neurons, and more.

NASA plans to test whether DNA sequencing studies can be conducted in microgravity.

Congress passes a continuing resolution to keep the US federal government funded through mid-December.

The Human Genome Project was launched 25 years ago, and at Nature, Francis Collins, James Watson, and Eric Green look back at the lessons learned.